1 A plasma proteomic signature links secretome of senescent monocytes to aging- and 2 obesity-related clinical outcomes in humans

- 3
- 4 Bradley Olinger^{*1,2}, Reema Banarjee^{*1}, Amit Dey¹, Dimitrios Tsitsipatis⁴, Toshiko Tanaka¹, Anjana
- 5 Ram¹, Thedoe Nyunt¹, Gulzar Daya³, Zhongsheng Peng³, Linna Cui¹, Julián Candia¹, Eleanor M.
- 6 Simonsick¹, Myriam Gorospe⁴, Keenan A. Walker³, Luigi Ferrucci¹, Nathan Basisty¹
- 7 *Contributed equally
- 8
- ⁹ ¹Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, Maryland, USA.
- ²Department of Biology, Johns Hopkins University, Baltimore, Maryland, USA
- ¹¹ ³Laboratory of Behavioral Neuroscience, National Institute on Aging, NIH, Baltimore, Maryland,

12 USA

- ¹³ ⁴Laboratory of Genetics and Genomics, National Institute on Aging, NIH, Baltimore, Maryland,
- 14 USA
- 15
- 16
- 17
- 18 Correspondence:
- 19 Nathan Basisty, PhD
- 20 nathan.basisty@nih.gov

21

22

23

24 Abstract

25 Cellular senescence increases with age and contributes to age-related declines and pathologies. 26 We identified circulating biomarkers of senescence associated with diverse clinical traits in humans to facilitate future non-invasive assessment of individual senescence burden and efficacy 27 testing of novel senotherapeutics. Using a novel nanoparticle-based proteomic workflow, we 28 profiled the senescence-associated secretory phenotype (SASP) in monocytes and examined 29 30 these proteins in plasma samples (N = 1060) from the Baltimore Longitudinal Study of Aging 31 (BLSA). Machine learning models trained on monocyte SASP associated with several age-related 32 phenotypes in a test cohort, including body fat composition, blood lipids, inflammation, and 33 mobility-related traits, among others. Notably, a subset of SASP-based predictions, including a 'high impact' SASP panel that predicts age- and obesity-related clinical traits, were validated in 34 InCHIANTI, an independent aging cohort. These results demonstrate the clinical relevance of the 35 36 circulating SASP and identify relevant biomarkers of senescence that could inform future clinical 37 studies.

38 Introduction

39

40 Cellular senescence, a hallmark of aging¹, is a state of permanent cell-cycle arrest in response to a variety of sublethal stresses, such as DNA damage, oxidative stress, metabolic imbalance, and 41 42 telomere erosion². Despite being in replication arrest, senescent cells remain metabolically active and secrete a plethora of proteins and other biomolecules, including cytokines, chemokines, 43 metalloproteases, and growth factors, collectively known as the senescence-associated secretory 44 phenotype (SASP)³. With increasing age, senescent cells accumulate in various tissues¹ and, at 45 least partially via the SASP, contribute to diverse age-related pathologies, including cognitive 46 decline⁴⁻⁷, cardiovascular disease⁸, and immune dysfunction⁹⁻¹¹, among others¹²⁻¹⁴. Importantly, 47 selective elimination of senescent cells and modulation of the SASP by senotherapeutic 48 49 interventions are effective strategies to improve age-associated pathologies in preclinical models^{7,15,16}. Thus, developing methods to identify and eliminate senescent cells in humans is a 50 51 promising goal for improving healthspan.

In recent years, senescence of immune cells, including monocytes, have been implicated 52 as a potentially key driver of age-related pathologies. Senescence of immune cells increases with 53 age and is thought to contribute to an age-related increase of sterile inflammation -54 "inflammaging" — and higher susceptibility to infectious diseases¹⁷. Additionally, higher levels of 55 56 senescence in the immune system drive systemic aging and propagate senescence in solid 57 organs, such as the liver, kidney and lung¹⁸. There is emerging evidence that senescent monocytes accumulate in vivo in humans. These circulating immune cells form up to 10% of the 58 59 total white blood cells and are involved in pathogen recognition via Toll-like receptors (TLRs) and 60 regulation of inflammation. A proinflammatory phenotype of monocytes has been attributed to senescence in the elderly¹⁹. Notably, circulating monocytes express a senescence-like signature 61 in vivo in subjects with severe COVID, and SASP from these monocytes was associated with 62 increased severity of the infection, suggesting an important role of senescent monocytes in 63 mediating systemic inflammation in COVID patients²⁰. Moreover, monocytes are promising 64 sources of biomarkers due to their abundance in blood. Despite their potential involvement in 65 inflammaging and biomarker potential, the role of monocyte senescence-associated proteins in 66 aging and their potential as clinical biomarkers are poorly characterized. 67

68 Quantifying circulating biomarkers of senescence holds clinical potential for identifying 69 outcomes tied to senescence, enabling non-invasive determination of individual senescence 70 burden for risk stratification, and tracking the effectiveness of senotherapeutics in clinical 71 trials^{21,22}. In recent years, high-throughput proteomic studies have quantitatively profiled

senescence-associated proteins in circulation and demonstrated their associations with diverse aging-related outcomes in humans²¹⁻²³, including mortality, multimorbidity, strength and mobility. These studies leveraged human cohorts, such as InCHIANTI (Invecchiare in Chianti), BLSA (Baltimore Longitudinal Study of Aging), GESTALT (Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing), Lifestyle Interventions for Elders (LIFE), and others²⁴⁻³⁰. However, no biomarker studies to date have comprehensively characterized the monocytespecific SASP and evaluated its clinical utility as circulating biomarkers in humans.

79 The primary goal of this study is to comprehensively profile the monocyte SASP in serum-80 supplemented culture conditions and evaluate its clinical utility as a circulating biomarker in 81 humans. We adopted a novel automated nanoparticle-based workflow previously leveraged for analysis of plasma³¹ that overcomes the challenges associated with mass spectrometry (MS)-82 83 based profiling of serum-supplemented medium. Thus, we completed the first comprehensive MS analysis of SASP that is not confounded by serum-free culture conditions, which are widely used 84 85 for MS-based quantification of SASP from cell-culture experiments³². Moreover, we evaluated the senescent monocyte signatures in the plasma proteome of the BSLA study. We identified 86 signatures of SASP, including a high-impact panel, that predict age-related and obesity-87 88 associated clinical traits in a test cohort. Remarkably, SASP-based clinical trait associations were 89 replicated in InCHIANTI, an independent aging study.

90

91 Results

92

93 Optimization of senescence in monocytes and development of a biomarker discovery 94 pipeline

To develop a rigorously validated model of cellular senescence in monocytes (Fig. 1a), senescent 95 THP-1 monocyte cells were generated with multiple protocols, and an optimal method was 96 97 selected, based on the expression of a combination of senescence biomarkers and cell viability. Senescence was induced in THP-1 monocytes with varying doses of gamma irradiation (IR) and 98 assessed at various time points after IR. To test viability and proliferation, THP-1 cells in complete 99 100 medium were exposed to different doses of IR (5, 7.5 and 10 Gy) and cell viability measurements 101 at 24-h intervals up to 13 days confirmed that these doses are not lethal (Fig. S1a). However, cell proliferation was inhibited after exposure to 7.5 and 10 Gy as seen by reduced incorporation of 102 5-ethynyl-2'-deoxyuridine (Edu) in the treated cells (Fig. 2a-b; Fig S1g). Further, the expression 103 104 levels of a panel of senescence marker mRNAs (GDF15 mRNA, CDKN2A (p16) mRNA and 105 CDKN1A (p21) mRNA) and mRNAs encoding SASP factors (e.g., IL1A and IL6 mRNAs) were

significantly higher in IR-treated cells than proliferating controls (**Fig. 2c; Fig. S1b-e**). Elevated levels of SPiDER β -gal in IR-treated cells further confirmed the stable induction of senescence 7 days after exposure to 7.5 Gy (**Fig. 2d; Fig. S1f**). Given the stable cell-cycle arrest, viability, and expression of senescence-associated mRNAs at this dose, we used 7.5 Gy IR radiation and 7 days in culture in all later experiments.

111

112 Identification of the monocyte SASP in standard culture conditions

113 MS-based proteomic analysis is notoriously challenging in serum-supplemented cell-culture conditions due to the highly dynamic range of serum proteins³³. In standard cell-culture conditions, 114 115 fetal bovine serum (FBS) introduces a high concentration of exogenous proteins that hinder the detection of endogenously secreted proteins from cultured cells at lower levels. To overcome 116 117 these challenges, we applied a novel proteomic platform that was previously used to analyze blood samples³⁴⁻³⁶. An automated robotic platform utilizes nanoparticle-based enrichment of 118 119 protein coronas for a deep and unbiased identification of proteins in high-dynamic-range samples (Proteograph[™] XT Assay, Redwood City, CA) ³¹. Reasoning that serum-supplemented medium 120 faces essentially the same challenges as serum itself, we applied this instrumentation in 121 122 combination with a multi-species proteomic analysis (bovine + human) to comprehensively and 123 quantitatively profile the monocyte SASP (Fig. 1b). Briefly, data independent acquisition (DIA) 124 MS-based proteomics was conducted on the secretomes of senescent and non-senescent 125 monocytes processed with the nanoparticle workflow (n=14), as well as matched samples 126 processed with no nanoparticle separation (n=6) to compare with a standard workflow. Using the 127 standard workflow, 3,935 proteins (24,875 peptides) were identified, and weak separation between senescent and non-senescent secretome was evident by principal component analysis 128 129 due to interference from the supplemented bovine proteins (Fig. 3a). In contrast, the nanoparticlebased workflow enabled the detection of 10,089 proteins (96,511 peptides) and identified 130 131 differences in the two secretomes as evident in principal component analysis (Fig. 3b-c); these values represented a significant improvement over our reported secretome studies³⁰. Additionally, 132 even though protein expression was positively correlated on the peptide and protein level between 133 neat and nanoparticle-processed samples (Fig. S2a,b), the reproducibility of protein 134 135 measurements was improved after processing (Fig. S2c). Any peptides that matched bovine 136 proteins, as well as those shared between human and bovine, were removed, and the remaining 137 6,161 human proteins were compared between senescent and non-senescent secretomes. 138 Senescent secretomes had 3.413 increased proteins and 180 decreased proteins, compared to 139 controls (Fig. 3d). Gene Ontology analysis of the top 200 upregulated proteins indicated

140 enrichment of biological processes such as response to interferons, a known senescence-141 associated pathway, and transmembrane transport (Fig. 3e). Furthermore, a comparison of the 142 monocyte SASP with that of fibroblasts using the SASP Atlas (http://www.saspatlas.com/)³⁰ revealed 237 proteins, or 43% of the fibroblast SASP proteome, overlapped with the monocyte 143 SASP proteome (Fig. 3f). Ontology analysis reveals that these proteins are involved in multiple 144 biological processes, including cellular detoxification and regulation of apoptotic processes and 145 oxidative stress-induced pathways (Fig. 3g). Interestingly, these pathways were also reported 146 among the fibroblast core SASP³⁰. Full proteomic replicate data, guantification, and statistics are 147 148 available in Table S1.

149

150 The senescent monocyte secretome is detectable in circulating plasma in BLSA

151 The clinical associations of the monocyte SASP in circulation were examined in the BLSA. This longitudinal study used multiple biochemical and clinical assessments to examine the 152 153 physiological and functional changes associated with healthy aging. BLSA participant characteristics are displayed in **Table 1**. This analysis utilized the plasma proteomic data from 154 the BLSA that had been acquired using the 7K SOMAscan Assay (Somalogic Inc., Boulder, CO), 155 which performs 7,288 protein measurements^{37,38}. Among the SomaScan protein panel, 1550 156 157 monocyte SASP proteins were measured in the BLSA (Fig. 4a, Table S2). To evaluate the age-158 associated clinical relevance of the monocyte SASP, we used Spearman correlation to identify 159 only the components of the monocyte SASP that were increasing in circulation across the lifespan 160 in the BLSA. Of the monocyte SASP in circulating plasma, 308 proteins were upregulated and 161 also positively associated with age (Table S2). To evaluate clinical traits associated with SASP regardless of covariate such as age, we utilized the full SASP panel (1550 proteins) including 162 163 covariates such as age, sex, and race in downstream clinical trait associations.

164

165 Monocyte SASP signatures predict mobility and obesity-associated clinical outcomes

To identify the most clinically relevant monocyte SASPs without model overfitting, elastic net 166 167 modeling was performed for unbiased feature selection of proteins that associate with a diverse 168 set of clinical outcomes, while controlling for age, sex, race, and kidney function as model 169 covariates. Clinically relevant SASP factors were identified for a panel of clinical traits, including mobility, inflammation, body composition, and metabolism-related measurements in the BLSA 170 (Fig. 4b). For each trait, a different subset and number of biologically relevant proteins were 171 172 identified and subsequently referred to as elastic net-selected proteins (ENSPs) (Fig. 4c). One 173 established metric for validating biomarker candidates for clinical traits is their out-of-sample

174 predictive accuracy. This was examined in a cohort of 1,330 subjects from the BLSA, split into a 175 training dataset (80%) and test dataset (20%). Elastic net models that include ENSPs and 176 covariates were trained using the training dataset and used to predict clinical traits in the testing dataset. These Elastic Net models showed significant correlation between observed and 177 predicted values (FDR < 0.05) (Fig. 4b) for all clinical traits, and showed highest out-of-sample 178 trait prediction potential for Triglycerides (cor. = 0.8447), HDL (cor. = 0.8343), waist size (cor. = 179 180 0.7844), LDL (cor. = 0.7508), BMI (cor. = 0.6851), and 400-meter walking pace (cor. = 0.7085). (Fig. 4b), suggesting that these subsets of monocyte SASP are implicated in these clinical traits. 181 182 Elastic net models also outperformed a model using covariates alone (e.g., age, sex, race and kidney function) in predicting obesity (Fig. 4d). After adjusting for covariates, the size of the 183 regression coefficient for the SASP proteins in the elastic net model did not change substantially 184 185 (Fig. S3a), suggesting that ENSPs are not simply demonstrating association with clinical traits due to their association with age and might have age-independent clinical implications. 186

187

188 Association of SASP signatures with body fat depots and percentages

Because ENSPs had strikingly high predictive potential of clinical traits related to BMI and waist 189 190 size, we explored whether these associations were driven by fat in specific fat depots in the body. 191 We examined senescence markers and their predictive potential using elastic net modeling of 192 whole-body computed tomography (CT) and dual x-ray absorptiometry scans of the BLSA 193 participants. These measurements were used to quantify body fat content at various regions 194 across the body, including subcutaneous fat in the limbs and abdomen, visceral fat, and 195 intramuscular fat depots. A significant out-of-sample predictive potential was found across all body fat measures (Fig. 5a), utilizing ENSPs that were selected for each trait (Fig. 5b). 196 197 Correlations between ENSPs and body fat were relatively high across different fat depots, ranging from 0.5074 to 0.7473, with the highest correlation in trunk fat and the lowest in abdominal 198 199 subcutaneous fat. Moreover, total-body fat percentage was most strongly associated with 200 senescence signatures (Spearman Cor. = 0.7913) than any individual fat depot (Fig. 5a,d). Because fat percentage is adjusted for overall body size, these data suggest that overall 201 proportion of body fat, rather than the size of any specific fat depot, is associated with a monocyte 202 203 senescence-associated protein signature. ENSPs were also used to predict fat percent in an independent test cohort and outperformed a covariate-only (age, sex, race, eGFR) model when 204 205 predicting fat percent-based obesity (Fig. 5c), suggesting that ENSPs have age and covariate 206 independent predictive potential.

207

208 Validation of senescence signatures in an independent aging cohort

209 We next sought to further validate the role of monocyte SASPs in multiple phenotypes. We 210 performed a cross-validation analysis using plasma proteomic data from BLSA and InCHIANTI (demographics and clinical traits summarized in Table S3), a population-based study of older 211 individuals living in the Chianti geographic area of Italy, which was assessed using the 1.3k 212 213 SomaScan assay, an earlier version of the assay containing subset of the total protein 214 measurements in BLSA. We identified 220 monocyte SASP candidates detected in both cohorts that were selected for further testing for clinical trait associations. ENSPs were identified for 215 several clinical traits in both BLSA (Fig. S4a) and InCHIANTI (Fig. S4b). ENSPs identified in both 216 217 cohorts were used to train linear models used for cross-validation. These linear models, when trained on the BLSA cohort, significantly predicted several clinical traits in InCHIANTI (Fig. S4c), 218 219 and when trained on the InCHIANTI cohort, significantly predicted many clinical traits in the BLSA (Fig. S4d). These overlapping ENSP effectively cross-validated in both directions for several 220 221 clinical traits including BMI, triglycerides, and walking pace, among others in BLSA and InCHIANTI (Fig. 6a), indicating a robust ability of these proteins to predict clinical traits. 222 Additionally, a binomial model trained on overlapping ENSPs in BLSA predicted obesity in 223 224 InCHIANTI better than an age and sex-only model (Fig. 6b). The cross-validation potential of 225 ENSPs for a subset of clinical traits, such as BMI, blood pressure, triglycerides, and walking pace, 226 in geographically and genetically distinct human cohorts demonstrates their robust clinical 227 relevance.

228

A select senescence panel robustly predicts aging- and obesity-related outcomes

To explore whether a parsimonious subset of the total SASP would capture most of the 230 231 association between SASP proteins and multiple clinical traits, we prioritized and selected a smaller set of proteins based on their associations with multiple traits and relative importance. 232 233 Though a different subset of SASPs was selected for each trait, consistent with previous reports^{39,40}, notable features (proteins) were selected via elastic net modeling in several traits of 234 a fourteen-trait panel. Ranking the ENSPs by the number of features in which they were implicated 235 revealed that NQO1 and IL1RN were selected for eight of the fourteen traits, LMAN2, IGF2R, 236 237 KHSRP, and CCL18 were selected for seven of the fourteen traits. Twenty-one total ENSPs were identified in at least five of the sixteen traits, seven of which were also quantified in the InCHIANTI 238 239 1.3k panel (Fig. 7a). Linear models of the high impact panel that were trained on 80% of the BLSA cohort significantly predicted many clinical traits of the remaining 20% test set (Fig. 7b). Similarly, 240 241 high impact panel linear models show held-out predictive potential when trained on 80% of the

242 InCHIANTI cohort and tested in the remaining 20% (Fig. 7c). Next, the high impact panel 243 expression levels were condensed into a single continuous variable using principal component 244 analysis. In this way, principal component 1 was used to represent each individual's senescence burden score. Ranking the BLSA and InCHIANTI cohorts by their compositive senescence burden 245 and plotting linear trends of the clinical traits walking pace, HDL, BMI, and CRP reveals that 246 247 increasing senescence burden score shows the expected association with trait trending in the direction of poorer health (positively associated with BMI and CRP, negatively associated with 248 walking pace and HDL), in both BLSA (Fig. 7d) and InCHIANTI (Fig. S5b). This suggests that 249 the high impact panel could potentially be used as a proxy metric of individual senescence burden 250 251 in a clinical setting.

252

253 Validation of age and covariate independent clinical relevance of senescence signatures

To evaluate the contribution of covariates such as age to the predictive potential of elastic net 254 255 models, we compared covariate-only models to combined ENSP + covariate models. To select 256 senescence signatures that are implicated in clinical traits irrespective of age and other covariates, such as race, sex, and estimated glomerular filtration rate (eGFR, a common marker 257 258 of kidney function), these metrics were included in the elastic net modeling performed thus far 259 and therefore contributed to the predictive potential of these models. To determine if the ENSPs 260 show age and covariate independent predictive potential, analysis of variance (ANOVA) testing 261 was used to compare covariate-only models to those that include ENSPs. ANOVA testing 262 revealed that including ENSPs in linear models significantly improved the accuracy of covariate-263 only linear models (**Table S4**) Additionally, including ENSPs in covariate-only linear models 264 substantially increased correlation coefficients (Fig. S3a), and ENSP-only models produced 265 similar correlation coefficients to ENSP with covariates models (Fig. S3a). Due to association with body fat, a similar analysis was conducted using whole-body fat percent as an additional covariate 266 267 along with age, sex, race, and eGFR to determine if ENSPs show body-fat independent predictive 268 potential. ANOVA testing again revealed that ENSPs added significant additional predictive 269 accuracy to models using only body fat and other covariates (**Table S4**), and adding ENSPs to 270 body fat percent with other covariate-only linear models again increased the correlation coefficient 271 for many clinical traits, particularly triglycerides, HDL, LDL, CRP, and fasting glucose (Fig. S3b). 272 Additionally, for each clinical trait, the predictive potential of ENSPs was compared with a 273 randomly selected group of proteins of the same group size. Permutation tests (100,000 274 repetitions per trait) revealed that ENSPs often demonstrated better out-of-sample trait prediction 275 potential than randomly selected proteins (Fig S5a, Table S5). These results implicate

senescence-associated proteins in BMI and other clinical traits independently of the effects ofaging and other covariates.

278

279 Discussion

280

This study applied a novel nanoparticle-based MS strategy to identify SASPs from monocytes in 281 282 fully supplemented culture conditions and revealed circulating senescence signatures that predict aging-associated clinical traits in humans. MS-based proteomics allows a comprehensive 283 unbiased characterization of the cell secretome. Yet, the large numbers of proteins, such as 284 albumin in FBS, in most culture media are a major hurdle in MS-based analysis of SASP proteins. 285 Our group and others addressed this issue by using serum-free media^{30,32,41-44}. However, 286 prolonged absence of serum profoundly alters cellular phenotypes, metabolism, and viability. We 287 initially observed dramatic loss of viability and induction of differentiation under serum starvation 288 289 in THP-1 cells (data not shown), necessitating a new approach compatible with serum supplementation. Serum starvation can also trigger inhibition of mTORC1, initiate autophagy⁴⁵ 290 291 and reduce protein synthesis, which greatly alter the global proteome of the cells and degrade 292 the reliability of markers from the secretome. Moreover, mTOR is a potent regulator of the SASP 293 in cultured cells^{46,47}. Application of the automated, nanoparticle-based workflow here enabled the 294 comprehensive profiling of the SASP in THP-1 monocytes under fully supplemented culture 295 conditions and free of the confounders of starvation.

296 Our workflow adapted a recent technology that enables comprehensive proteomic 297 analysis of the circulating proteome. This workflow leverages nanoparticles to aid in comprehensive detection of proteins in samples with a large dynamic range of protein 298 concentrations^{31,35,36,48}. In this approach, the protein mixture bound at the surface of nanoparticles 299 300 in a protein sample, termed the 'protein corona', contains a reduced protein dynamic range and 301 allows the detection and quantification of proteins that are normally undetectable in blood. The 302 composition of the protein corona is reproducible and quantitative and, therefore, can be utilized for blood biomarker studies^{31,36,49,50}. Because serum supplementation essentially produces the 303 304 same dynamic range problem as conditioned medium, we reasoned that the same workflow would 305 enable the comprehensive, quantitative, and unbiased profiling of the SASP under fully 306 supplemented culture conditions. Indeed, we detected a dramatically increased number of human peptides in conditioned medium supplemented with FBS. 307

308 Despite the differences in the workflow and cell types between this study and our 309 published SASP Atlas³⁰, which focused on senescence signatures in fibroblasts, there were

310 notable similarities in the composition of the SASPs. Here, we detected at least a threefold 311 increase in the SASP proteins versus SASP Atlas proteins. This is likely due to a combination of 312 factors, likely including the different MS instrumentation and the fact that SASP factor secretion is greater in serum-supplemented conditions. Nonetheless, more than 40% of the published 313 irradiation-induced fibroblast SASP factors were also detected in the inducer-matched monocyte 314 315 SASP from the current study. Among the key pathway similarities were cellular detoxification and regulation of apoptotic processes and oxidative stress-induced pathways. Furthermore, the 316 317 current study identified other well-known signatures of senescent cells. Prominent among these were highly elevated interferon-related proteins (Fig. 3e) and, most significantly, MX1, ISG15 and 318 319 IFITM3 (FDR < 1e-25). Among all SASP factors, MX1 exhibited the largest and most significant protein increase (55-fold change, FDR = 2.23e-14). Notably, multiple interferon-response 320 321 associated proteins significantly elevated in the monocyte SASP (FDR < 0.05) are among the proteins increased with age in plasma of BLSA participants (FDR < 0.05), including IFI16, OAS1, 322 323 IFIH1, IFNGR1, IF9, IRF4, OASL and related pro-inflammatory cytokines. Moreover, OASL was 324 selected among other top proteins in our high impact senescence panel (Fig 7a) based on its 325 association with multiple clinical traits and ranked highest in the panel in importance, based on 326 the average magnitude of its association with each trait. Collectively, these results further 327 reinforce the robustness of the type-1 interferon response in senescent phenotypes and highlight 328 their potential as senescence-associated biomarkers in circulation.

329 Our results are consistent with the premise that senescent cells, particularly senescent 330 monocytes, may either contribute to or be driven by declines in diverse age-related and obesity-331 related clinical outcomes, including loss of mobility, increased body fat (BMI, fat percentage, waist size), increased blood pressure, elevated triglycerides and lipids, elevated glucose and A1C, and 332 333 inflammation (CRP and IL6). These findings are also consistent with previous studies in multiple aging cohorts identifying senescence markers that are associated with diverse clinical traits of 334 335 aging, such as frailty and cognitive decline. For example, SASP proteins, such as ICAM1, MMP7 and Activin A, have been associated with a decline in physical activity in participants of the LIFE 336 337 study²⁸. In addition, plasma levels of 13 core SASP proteins, including CTSB, a component of the monocyte SASP, are associated with all-cause mortality and multimorbidity in the BLSA²⁵. Few 338 339 of the published SASP-derived protein associations were observed in the present study. highlighting the heterogeneity in senescent cell phenotypes based on cell-type. For example, 340 GDF15 is notably missing from the monocyte SASP, while the most important SASP proteins 341 (based on the number of associations, Fig 7a) identified in the present study are not among 342 343 circulating senescence factors currently described²². These results are in line with the expected

heterogeneity of senescent cells based on cell type, and that diverse SASP emerging from different senescent cell populations might drive different phenotypes. These results further suggest the importance of developing type-specific (senotype-specific) senescence biomarker signatures for drawing connections between senotype and phenotype in future studies.

One of the striking findings of this study are the robust associations between the monocyte 348 349 SASP and obesity-related outcomes, such as BMI and body fat, which were among the strongest 350 associations observed. Of note, elastic net models based on monocyte SASP predicted out-of-351 sample waist size, triglycerides, fat mass in multiple compartments, BMI, fasting glucose, A1C. 352 and blood pressure. An exploratory analysis of body-fat depots in the BLSA revealed that fat 353 deposits in different locations, including thigh, arms, abdomen, and different types, including visceral, subcutaneous, and intramuscular, were all strongly predicted by a monocyte SASP 354 355 elastic net model (Spearman correlation ranging from = 0.5074 to 0.7473, Fig 5a). However, body 356 fat percentage, a measure of body fat corrected to overall body size, was most strongly predicted 357 (cor=0.7913), suggesting that fat proportion, rather than overall mass, is likely associated with 358 senescence. The associations of monocyte SASP and body fat and related outcomes is notably independent of age and other covariates (Fig S3a, Table S4). These results suggest a potential 359 360 link between monocyte senescence and obesity. While the direction of causality cannot be 361 definitively determined in the present study, there is ample evidence to support obesity as a driver 362 of cellular senescence. Culture conditions that mimic aspects of obesity, such as high free-fatty 363 acids or glucose, can drive cells into senescence in vitro ⁵¹⁻⁵³. Senescent cells accumulate in 364 obesity and high-fat diet, particularly in adipose tissue^{54,55}. Furthermore, the transplantation of 365 senescent preadipocytes into mice fed high fat diet exacerbates declines in walking speed and endurance when compared with normal diet⁵⁶. Obesity drives senescence in glial cells in mouse 366 brains and their removal resulting in restored neurogenesis⁵⁷. Thus, evidence strongly points to 367 obesity as a disease-associated senescence inducer that can be decoupled from aging. 368 369 Additionally, results from the CALERIE trial demonstrate the reduction of senescence biomarkers 370 in individuals over 1-2 years of calorie restriction, further suggesting a link between senescence burden and diet, body composition and metabolism⁵⁸. We speculate that at least some of the 371 clinical traits described in this study can be attributed to obesity-associated senescent cells. 372 373 Indeed, we observe that monocyte SASP-based elastic net models predict key obesity-associated 374 clinical outcomes related to metabolism (fasting glucose, A1C), lipids (triglycerides, cholesterol), 375 and blood pressure. Collectively these findings suggest the importance of considering obesity as 376 a contributor to senescence and senescence-associated outcomes in humans. Importantly, these 377 associations suggest that obese individuals may be among those that benefit most from

senotherapeutic interventions, and we propose that this population should be considered forinclusion in future trials of senolytics and senomorphics.

380 Given the known age-associations of senescent cells and many SASPs, one of the potential concerns of the present study, and all studies of senescence, are the potential 381 contribution of covariates such as aging to the associations with age-related clinical outcomes, 382 383 and whether they can be separated from age-related processes. In this study, we were indeed 384 able to show that predictive models based on SASP added value to models that include covariates 385 (age, sex, race, and eGFR) and were clinically meaningful in predicting outcomes such as obesity. 386 Further, to mitigate the risk of overfitting our models, which are based on large numbers of features, elastic net modeling was leveraged in this study. To further test the strength of the 387 model, we were able to show that our elastic net model selected on monocyte SASP far 388 389 outperformed linear models based using the same number of randomly selected proteins across the 7k SomaScan assay (Fig S5a). To ensure the robustness of the findings, we report 390 391 associations are based on prediction out-of-sample clinical outcomes (independent of the training 392 set), including a subset of the clinical associations that replicated across BLSA and InCHIANTI 393 (Fig 6a).

394 One of the clinically meaningful findings of his study was that, despite the large number of 395 total SASP proteins identified, a relatively small panel of these also robustly predicted a set of 396 age- and obesity-associated clinical outcomes, including inflammation (IL6, CRP), lipids (HDL, 397 LDL), glucose (A1c, fasting glucose), blood pressure, walking speed and pace, and BMI. Notably, 398 even though a fraction of this panel was measured in both BLSA and InCHIANTI for replication, 399 multiple predictions were replicated across aging studies, supporting the robustness of using 400 selected high impact proteins, for clinical associations. A defined panel of proteins may be 401 clinically advantageous in that the full panel, or selected proteins, can be more readily tested and applied in multiple studies without building new models or making costly measurements of large 402 403 numbers of proteins. In future studies, it will be of interest to further validate this panel in diverse 404 human cohorts and test their utility to predict a range of aging- and obesity-related outcomes. 405 Several proteins in the panel are consistent with senescence biology and have known associations with outcomes with elevated senescent cell burden. Notably, the cytokine CCL18 406 407 (also known as PARC) previously showed the strongest association with mortality among 28 SASPs in a study of 1923 individuals over the age of 65⁵⁹, and has been associated with disease-408 progression or negative outcomes in a range of diseases including cancer ⁶⁰, atherosclerosis ⁶¹, 409 410 and lung disease ⁶². Glycoprotein nonmetastatic melanoma protein B (GPNMB) is a senescence-411 associated protein that, when targeted with a senolytic vaccine, results in the reduction of

412 senescence burden and improvements in aging and obesity-related outcomes in mice, including 413 improved glucose homeostasis on high fat diet, and reduced aortic plaque size in APOE KO 414 mice⁶³. LGALS3BP is a previously reported core SASP³⁰, is associated with diverse 415 malignancies⁶⁴ and sepsis⁶⁵. In future studies, it will be valuable to validate the associations of 416 the set of proteins in the high impact senescence panel with elevated senescence burden and 417 evaluate their potential roles as either drivers or biomarkers of disease outcomes.

This study has several limitations. SASP factors in plasma can be contributed by a variety 418 419 of cells and tissues in the body. Thus, it is not possible to track the originating tissues of SASPs in circulation or to verify whether circulating proteins were released by senescent cells or other 420 421 secreting cells with common secretory factors, such as activated immune cells. Senescence signatures are numerous and heterogeneous by cell type³, and examining clinical associations of 422 423 senescence signatures from a variety of tissue types is warranted. Studying the SASP from 424 specific cell types can help dissect the role of individual cells in the progression of age-associated 425 clinical traits. In future studies, it may be of interest to identify tissue-specific (senotype-specific) 426 senescent signatures and examine their clinical associations in human cohorts. These studies 427 may shed light on the contributing tissue and senotype-specific senescent cell populations on 428 aging- and obesity-related outcomes and identify more sensitive and specific biomarkers. One 429 limitation of the cross-study validation performed is the difference in the proteomic panels applied 430 in each study, where the BLSA was performed on the newer generation of the SomaScan panel 431 versus the InCHIANTI study. While this affected the strength of the predictions, multiple outcomes 432 remained significant with smaller panels, highlighting some of the more robust associations. It will 433 be valuable going forward to test the cross-study validations both in studies that utilize the complete proteomic assay, and in studies that utilize different proteomic platforms such as UK 434 435 Biobank, to better understand the predictors that are most robust to differences in proteomic methods. Finally, longitudinal proteomic measurements will be useful in future studies for 436 437 evaluating whether SASP protein trajectories can be more sensitive in predicting clinical 438 outcomes.

In summary, we showed that SASP factors from monocytes have a high association with aging-associated clinical traits and can serve as biomarkers to predict biological aging. Using nanoparticle-based enrichment coupled with MS enabled comprehensive characterization of the secretome from senescent monocytes in culture in serum-supplemented culture conditions. Our results highlight a novel approach to study the cellular secretome under physiological conditions. Moreover, this study sheds light on clinical associations of circulating monocyte SASPs in human

- longitudinal studies and identifies possible biomarkers of senescence that could potentially inform
- 446 future senotherapeutic trials in obese and aged individuals.
- 447

448 Methods

449 Cell culture and senescence induction

450 THP-1 human monocytes (ATCC, Manassas, VA; #TIB-202) were cultured in RPMI 1640 medium (Thermo Fisher Scientific Inc., Waltham, MA; #11875119) supplemented with 10% FBS (Thermo 451 Fisher Scientific; #26140079) and 1% pen strep (Thermo Fisher Scientific; #15070063) in a 20% 452 453 O₂, 5% CO₂ incubator. To determine the optimum conditions for induction of senescence in monocytes, proliferating THP-1 cells were exposed to different doses of ionizing (y) radiation (IR: 454 455 5, 7.5, and 10 Gy) using the Gammacell 40 Exactor, a Cesium-137 based irradiator (Nordion Inc., 456 Canada); thereafter, cell viability and senescence markers were assessed over different 457 timepoints. Cell viability was measured using the CellTiter-Glo® Luminescent Cell Viability Assay 458 (Promega Corporation, Madison, WI; #G7570) as per the manufacturer's instructions. IR radiation 459 of 7.5 Gy and culture up to 7 days were optimum for senescence induction and were used for all 460 further experiments. Proliferating cells were used as non-senescent controls for all experiments.

461

462 EdU incorporation assay

Cell proliferation was assessed using the Click-iT™ Plus EdU Cell Proliferation Kit (Thermo Fisher 463 Scientific; #C10640), following the manufacturer's instructions. Briefly, 20,000 cells per well were 464 seeded in 100 µL of medium in 96-well plates. At 6 days after irradiation, cells were incubated 465 with 20 µM 5-ethynyl-2'-deoxyuridine (EdU) overnight at 37°C. Next day, cells were fixed using 466 467 3.7% formaldehyde for 15 min, followed by permeabilization with 0.5% Triton X-100 for 20 min. 468 Cells were then incubated with Alexa Fluor picolyl azide and Hoechst 33342 dye for 30 min each. The resulting images were captured by a fluorescence microscope (BZ-X Analyzer, Keyence 469 470 Corporation, Itasca, IL). The percentage of cells that showed EdU incorporation corresponded to the percentage proliferating cells. 471

472

473 Quantitative PCR (qPCR) analysis

Total RNA was isolated using a Direct-zol RNA Miniprep Kit (Zymo Research, Irvine, CA;
#R2052), and 500 ng of total RNA was reverse transcribed using Maxima reverse transcriptase
(Thermo Fisher Scientific; # EP0741) and random hexamers. For reverse transcription followed
by quantitative RT-qPCR analysis, 0.1 μl cDNA was employed with 250 nM of gene-specific

478primers (Table S6) and KAPA SYBR® FAST qPCR Kits (KAPA Biosystems Inc., Wilmington, MA;479#) on the QuantStudio 3 Realtime PCR system (Thermo Fisher Scientific). Relative RNA levels480were calculated after normalizing to *ACTB* mRNA encoding the housekeeping protein β-actin481using the $2^{-\Delta\Delta Ct}$ method. QPCR experiments were performed with seven biological replicates of482IR-treated and proliferating controls. Statistical analysis was performed using GraphPad Prism483v10. Results are presented as the mean ± SD. Comparisons between the two groups were made484using students *t*-test. Statistical significance was considered at p < 0.05.</td>

485

486 Senescence-associated β-galactosidase (SA-β-gal) assay

Senescence-associated β-galactosidase (SA-β-gal) activity was assessed using the Cellular Senescence Plate Assay Kit - SPiDER- β Gal (Dojindo Molecular Technologies Inc., Rockville, MD; #SG05), following the manufacturer's instructions. Briefly, 150,000 cells were seeded in 2 mL of medium in 6-well plates. On the 7th day after IR, cells were lysed and incubated with SPiDER βgal for 1 h at 37°C, and SPiDER β-gal fluorescence intensity was measured at 535 nm excitation and 580 nm emission using a microplate reader.

493

494 Sample preparation for mass spectrometry

495 SASPs from senescent and proliferating THP-1 monocytes were collected, based on a modified 496 version of the protocol from Neri et al.³², adjusting the protocol so that complete medium 497 (supplemented with 10% FBS) was used in place of serum-free medium because of the 498 downstream processing of samples with the Proteograph workflow. Briefly, THP-1 cells were 499 grown in T75 flasks to sub-confluence prior to induction of senescence. For senescent samples, 500 cells were shifted to fresh complete medium 7 days after irradiation, and conditioned medium 501 containing SASP was collected after 48 h. Conditioned media from proliferating cells were 502 similarly collected after 48-h incubation in fresh complete medium. Conditioned medium was then 503 centrifuged at 10,000 x g for 15 min to pellet down cell debris and concentrated using 3 kDa 504 molecular mass cut-off filters. One milliliter of each conditioned medium sample was then 505 aliquoted into tubes for downstream preparation, for a total of 14 samples (seven senescent and 506 seven non-senescent).

507 The conditioned medium samples were processed as described³⁴ on the SP100 508 Automation Instrument coupled with Proteograph XT Assay Kits (Seer, Inc). Briefly, samples were 509 incubated with two chemically distinct nanoparticle suspensions supplied in the assay kits. 510 Nanoparticle-bound proteins were captured by incubation and a series of gentle washes. The 511 resulting protein coronas were reduced, alkylated, and digested with Trypsin/Lys-C to generate

512 peptides for MS analysis. The peptide mixture was desalted using solid phase-extraction. All steps 513 in the preparation of peptides were conducted automatically by the SP100, which produces two 514 peptide fractions per sample, one fraction for each nanoparticle suspension.

In addition to the preparation of 14 nanoparticle-processed samples, six matched neat 515 samples were prepared (three senescent and three non-senescent). Neat samples were 516 517 processed in parallel with the other samples, except no nanoparticles were added and no protein 518 corona was captured. Essentially, neat samples are equivalent to a standard digestion protocol and are used for comparison against standard methods. After processing of samples with the 519 520 Proteograph XT workflow, 34 peptide samples were generated for downstream MS analysis: 28 521 experimental samples (14 replicates with two nanoparticle fractions each) and six matched neat 522 samples.

523

524 Liquid chromatography–mass spectrometry

525 All samples were analyzed using a Vanquish Neo UHPLC system coupled to an Orbitrap Astral 526 mass spectrometer (Thermo Fisher Scientific) with a NanoSpray Flex source (Thermo Fisher 527 Scientific). Peptides (400 ng of each sample) were loaded on Acclaim PepMap 100 C18 (0.3 mm 528 ID x 5 mm) trap column and then separated on a 50-cm µPAC analytical column (PharmaFluidics, 529 Belgium) at a flow rate of 1.0 µL/min using a gradient of 4-35% solvent B (0.1% formic acid in 530 acetonitrile) mixed into solvent A (0.1% formic acid in water) over 20.8 min and a total run time of 531 24 min. The MS data were acquired in data-independent acquisition (DIA) mode with a normalized 532 HCD-collision energy of 25% and a default charge state of +2. MS1 spectra were acquired in the 533 Orbitrap every 0.6 s at a resolving power of 240,000 at m/z 200 over m/z 380-980. The MS¹ 534 normalized AGC target was 500% (5x10⁶ charges) with a MaxIT of 5 ms. For MS/MS experiments, 535 the DIA experiment was set to have a 3 m/z isolation window making 199 DIA scan events across the precursor isolation windows spanned 380-980. MS2 scans were collected from 150-2000 536 537 m/z. DIA MS² scans were acquired in Astral analyzer with a normalized AGC target of 500% 538 (5x10⁴ charges) to better control the ion population using MaxIT that was set to 5 ms. Window placement optimization was turned on. A source voltage of 1500 V and an ion transfer tube 539 temperature of 280 °C were used for all experiments. 540

541

542 **Protein identification and quantitative analysis pipeline**

543 Data were analyzed using the Proteograph[™] Analysis Suite (PAS) and the DIA-NN v1.8.1 544 algorithm to perform the peptide identification and quantification using an *in silico*-predicted 545 library, based on a combined database containing both Uniprot human and bovine proteomes

546 (4/2022 builds, 105,533 entries including isoform and TrEMBL). Match between runs was 547 enabled. Otherwise, all DIA-NN settings were set to default. FDR was set to 1% for filtering 548 identifications at the peptide and protein group levels. Peptide quantification was performed using a max representation approach, where the single quantification value for a particular peptide 549 550 represents the quantitation value of the nanoparticle most frequently measured across all 551 samples, and standard peptide-to-protein rollup was used on selected peptide values. 552 Furthermore, to specifically identify the monocyte SASP and eliminate proteins originating from the FBS and unambiguously remove non-human peptides, all the peptides that mapped to the 553 bovine proteome, or both human and bovine proteins, were removed from further analysis. Scaled 554 555 intensities of human-unique peptides were aggregated to generate protein intensities using the MaxLFQ algorithm, implemented in the R/Bioconductor package ig (version 1.9.12) ⁶⁶. Differential 556 557 analysis was conducted on the protein intensities between PRO and SEN samples using the R/Bioconductor package limma (version 3.58.1)⁶⁷. Multiple testing was corrected using the 558 559 Benjamini-Hochberg procedure.

560

561 **Pathway analysis**

Gene Ontology analysis was performed using ClusterProfiler version 4.6.0 68.69 in Rstudio to 562 563 identify the biological processes and molecular functions enriched among the differentially 564 expressed proteins. A background list of all proteins was utilized in each analysis. In Fig. 3e, the 565 background list of proteins included all human proteins identified by MS. In Fig. 3g, the background list consisted of all proteins identified in both the fibroblast and monocyte secretomes. 566 567 In Fig. 4c, the background list of proteins included all proteins that overlapped between the SomaScan 7K assay and the monocyte secretome proteins. All pathways depicted in main figures 568 569 were statistically significant after background correction and multiple-testing correction, with adjusted p < 0.05, calculated by the Benjamini-Hochberg Procedure. Analysis was conducted 570 using R version 4.2.0 (R Development Core Team, Vienna, Austria) and RStudio 2023.06.0-421 571 572 (RStudio, Boston, MA).

573

574 Clinical data

575 We used clinical data from the BLSA and InCHIANTI cohorts to determine the association of 576 senescence markers with physiological markers of health and aging. The BLSA study is a 577 population-based study that started in 1958 to evaluate the contributors of healthy aging in 578 subjects recruited from the DC/Baltimore metropolitan area that are 20 years old and older ⁷⁰⁻⁷². 579 It involves a data collection of clinical parameters, such as waist circumference, BMI and blood

580 pressure that are assessed during a standard medical exam. Blood tests were performed at a 581 Clinical Laboratory Improvement Amendments certified clinical laboratory at Medstar Harbor 582 Hospital, Baltimore, MD. Total cholesterol was measured using alkaline phosphatase, HDL and LDL with dextran magnetic beads, triglycerides with colorimetric methods, glucose with glucose 583 oxidase using the Vitros system (Ortho Clinical Diagnostics, Raritan, NJ). Serum inflammatory 584 585 markers IL6 (R&D System, Minneapolis, MN) and CRP (Alpco, Salem, NH) were measured with 586 enzyme-linked immunosorbent assay (ELISA). HbA1C levels were measured using liquid 587 chromatography by an automated DiaSTAT analyzer (Bio-Rad, Oakland, CA). Grip strength was measured three times on each of the right and left hand and the highest average grip strength 588 589 was reported. Usual gait speed was measured in two trials of a 6-m walk and the faster time 590 between the two trials is used for analysis. Body fat measurements were made using CT/dual x-591 ray absorptiometry scans. The BLSA protocol (03AG0325) was approved by the institutional 592 review board of the National Institute of Environmental Health Science, part of the National 593 Institutes of Health. To avoid possible confounding effects of medication use, patients taking 594 diabetes or hypertension medication had their A1C or blood pressure values excluded from 595 statistical analysis.

The InCHIANTI is a similar population-based study of aging conducted in the Chianti region of Tuscany, Italy previously described in more detail ⁷³. Residents from the population registry of Greve in Chianti (a rural area) and Bagno a Ripoli (near Florence) ranging in age from 21 to 102 years participated in the study. The study (exemption #11976) protocol was approved by Medstar Research Institute (Baltimore, Maryland), the Italian National Institute of Research and Care of Aging Institutional Review, and the Internal Review Board of the National Institute for Environmental Health Sciences (NIEHS). All participants provided written informed consent.

603

604 SOMAscan assay

The BLSA plasma proteomic study involved profiling for 7,596 SOMAmers using the 7K 605 606 SOMAscan Assay, whereas the InCHIANTI involved profiling for 1322 SOMAmers using the 1.3K 607 SOMAscan Assay at the Trans-NIH Center for Human Immunology and Autoimmunity, and 608 Inflammation (CHI), National Institute of Allergy and Infectious Disease, National Institutes of Health (Bethesda, MD). Proteomic assessment and data normalization for each of the assays 609 610 were conducted as reported^{37,74}. Plasma protein concentrations were directly proportional to the 611 abundance of the SOMAmer reagents that were reported in relative fluorescence units. The 612 reliability and variability of the SomaScan assay measurements has been previously rigorously evaluated and applied in the BLSA ^{37,75}. 613

614 Elastic-net modeling

615 To avoid overfitting of simple linear models, Elastic-net modeling, a penalized linear regression 616 machine learning technique, was used for feature selection of the most biologically relevant proteins. Elastic-net modeling was used due to its ability to perform unbiased feature selection, 617 and because it can cope with high collinearity of features. Elastic Net contains two tuning 618 parameters, alpha and lambda, that determine the nature of feature selection used. The value for 619 620 alpha can range from 0 (Ridge regression with no feature elimination) to 1 (Lasso regression which selects the smallest number of features). An alpha of 1 was used to apply the strictest level 621 of feature selection and reveal the smallest number of highly relevant features. The lambda 622 parameter determines the strength of the penalty, with a higher penalty eliminating more features. 623 The package glmnet⁷⁶ (version 4.1-6) randomly selected subsets of the dataset for cross-624 625 validation to find the lambda value with the smallest mean squared error. Due to its feature tuning method, this package produces slightly variable results. To account for this and to reduce 626 627 variability, the package was run 100 times for each trait, and the most accurate penalty term was 628 found across all runs.

629

630 Data Availability

All raw mass spectrometry data files and associated quantitative and statistical reports, metadata,
and supplemental data are available on MassIVE (dataset identifier: MSV000095315). FTP
download link: ftp://massive.ucsd.edu/v08/MSV000095315/.

634

635 Code Availability

636 R scripts for the core elastic net analysis described are available at 637 <u>https://github.com/geroproteomics/EN_Repeat/blob/main/EN_Repeat</u>.

638

639 Acknowledgements

This work was supported by the National Institute on Aging (NIA) Intramural Research Program
(IRP), NIH. N.B. was supported by a SenNet NIH Common Fund Grant (NIA U54 AG079779, PI:
Elisseeff) and a Hevolution GRO grant (HF-GRO-23-1199068-44). We gratefully acknowledge
Lauren Brick and NIDA/NIA Visual Media for assistance in figure preparation and Gary Howard
for editing of the manuscript.

- 645
- 646

647 **References**

1 López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. Hallmarks of 648 aging: An expanding universe. Cell 186, 243-278, 649 doi:https://doi.org/10.1016/j.cell.2022.11.001 (2023). 650 2 Hayflick, L. The limited in vitro lifetime of human diploid cell strains. Experimental Cell 651 Research 37, 614-636, doi:https://doi.org/10.1016/0014-4827(65)90211-9 (1965). 652 Tchkonia, T., Zhu, Y., Deursen, J. v., Campisi, J. & Kirkland, J. L. Cellular senescence 653 3 and the senescent secretory phenotype: therapeutic opportunities. The Journal of 654 655 Clinical Investigation 123, 966-972, doi:10.1172/JCI64098 (2013). 4 Zhang, X. et al. Rejuvenation of the aged brain immune cell landscape in mice through 656 657 p16-positive senescent cell clearance. Nat Commun 13, 5671, doi:10.1038/s41467-022-658 33226-8 (2022). 5 Baker, D. J. & Petersen, R. C. Cellular senescence in brain aging and 659 660 neurodegenerative diseases: evidence and perspectives. J Clin Invest **128**, 1208-1216, 661 doi:10.1172/JCI95145 (2018). Bussian, T. J. et al. Clearance of senescent glial cells prevents tau-dependent pathology 662 6 and cognitive decline. Nature 562, 578-582, doi:10.1038/s41586-018-0543-y (2018). 663 7 Ogrodnik, M. et al. Whole-body senescent cell clearance alleviates age-related brain 664 inflammation and cognitive impairment in mice. Aging Cell 20, e13296, 665 666 doi:10.1111/acel.13296 (2021). Childs, B. G. et al. Senescent intimal foam cells are deleterious at all stages of 667 8 atherosclerosis. Science 354, 472-477, doi:10.1126/science.aaf6659 (2016). 668 9 Walker, K. A., Basisty, N., Wilson, D. M., 3rd & Ferrucci, L. Connecting aging biology 669 and inflammation in the omics era. J Clin Invest 132, doi:10.1172/JCI158448 (2022). 670 671 10 Camell, C. D. et al. Senolytics reduce coronavirus-related mortality in old mice. Science 373, doi:10.1126/science.abe4832 (2021). 672 Yousefzadeh, M. J. et al. An aged immune system drives senescence and ageing of 11 673 solid organs. Nature 594, 100-105, doi:10.1038/s41586-021-03547-7 (2021). 674 12 Franceschi, C. & Campisi, J. Chronic Inflammation (Inflammaging) and Its Potential 675 676 Contribution to Age-Associated Diseases. The Journals of Gerontology: Series A 69, S4-677 S9, doi:10.1093/gerona/glu057 (2014). 13 Baker, D. J. et al. Naturally occurring p16lnk4a-positive cells shorten healthy lifespan. 678 Nature 530, 184-189, doi:10.1038/nature16932 (2016). 679 680 14 Chaib, S., Tchkonia, T. & Kirkland, J. L. Cellular senescence and senolytics: the path to the clinic. Nat Med 28, 1556-1568, doi:10.1038/s41591-022-01923-y (2022). 681 682 15 Baker, D. J. et al. Clearance of p16Ink4a-positive senescent cells delays ageingassociated disorders. Nature 479, 232-236, doi:10.1038/nature10600 (2011). 683 16 Childs, B. G. et al. Senescent cells: an emerging target for diseases of ageing. Nature 684 685 Reviews Drug Discovery 16, 718-735, doi:10.1038/nrd.2017.116 (2017). 17 Lee, K. A., Flores, R. R., Jang, I. H., Saathoff, A. & Robbins, P. D. Immune Senescence, 686 Immunosenescence and Aging. Frontiers in Aging 3, 2673-6217 (2022). 687 688 18 Yousefzadeh, M. J. et al. An aged immune system drives senescence and ageing of solid organs. Nature 594, 100-105, doi:10.1038/s41586-021-03547-7 (2021). 689 690 19 Ong, S.-M. et al. The pro-inflammatory phenotype of the human non-classical monocyte subset is attributed to senescence. Cell Death & Disease 9, 266, doi:10.1038/s41419-691 018-0327-1 (2018). 692 693 20 Lin, Y. et al. Circulating monocytes expressing senescence-associated features are 694 enriched in COVID-19 patients with severe disease. Aging Cell 22, 1474-9726, doi:10.1111/acel.14011 (2023). 695

| 696 | 21 | Dev, A. K. et al. Translating Senotherapeutic Interventions into the Clinic with Emerging |
|-----|----|---|
| 697 | | Proteomic Technologies. Biology (Basel) 12, doi:10.3390/biology12101301 (2023). |
| 698 | 22 | Survadevara, V. et al. SenNet recommendations for detecting senescent cells in |
| 699 | | different tissues. Nat Rev Mol Cell Biol, doi:10.1038/s41580-024-00738-8 (2024). |
| 700 | 23 | Basisty, N., Kale, A., Patel, S., Campisi, J. & Schilling, B. The power of proteomics to |
| 701 | | monitor senescence-associated secretory phenotypes and beyond: toward clinical |
| 702 | | applications. Expert Rev Proteomics 17, 297-308, doi:10.1080/14789450.2020.1766976 |
| 703 | | (2020). |
| 704 | 24 | Tanaka, T. et al. Plasma proteomic signature of age in healthy humans. Aging Cell 17, |
| 705 | | e12799, doi:10.1111/acel.12799 (2018). |
| 706 | 25 | Tanaka, T. et al. Plasma proteomic biomarker signature of age predicts health and life |
| 707 | | span. <i>eLife</i> 9 , e61073, doi:10.7554/eLife.61073 (2020). |
| 708 | 26 | Ubaida-Mohien, C. et al. Discovery proteomics in aging human skeletal muscle finds |
| 709 | | change in spliceosome, immunity, proteostasis and mitochondria. Elife 8, |
| 710 | | doi:10.7554/eLife.49874 (2019). |
| 711 | 27 | Tsitsipatis, D. et al. Proteomes of primary skin fibroblasts from healthy individuals reveal |
| 712 | | altered cell responses across the life span. Aging Cell 21, e13609, |
| 713 | | doi:10.1111/acel.13609 (2022). |
| 714 | 28 | Fielding, R. A. et al. Associations between biomarkers of cellular senescence and |
| 715 | | physical function in humans: observations from the lifestyle interventions for elders |
| 716 | | (LIFE) study. GeroScience 44, 2757-2770, doi:10.1007/s11357-022-00685-2 (2022). |
| 717 | 29 | Shin, JW., Lee, E., Han, S., Choe, SA. & Jeon, O. H. Plasma Proteomic Signature of |
| 718 | | Cellular Senescence and Markers of Biological Aging Among Postmenopausal Women. |
| 719 | | <i>Rejuvenation Research</i> 25 , 141-148, doi:10.1089/rej.2022.0024 (2022). |
| 720 | 30 | Basisty, N. <i>et al.</i> A proteomic atlas of senescence-associated secretomes for aging |
| /21 | | biomarker development. PLOS Biology 18, e3000599, doi:10.1371/journal.pbio.3000599 |
| 722 | 04 | (2020). |
| 723 | 31 | Blume, J. AO. X. <i>et al.</i> Rapid, deep and precise profiling of the plasma proteome with |
| 724 | 22 | Multi-hanoparticle protein corona. Nature Communications 11, 3662 (2020). |
| 725 | 32 | Analysis of the Sanagaanaa Accessisted Sacretery Departure by Data Independent |
| 720 | | Analysis of the Schescence-Associated Secretory Phenotype by Data-Independent |
| 727 | 22 | Acquisition. Cull Plotoc 1, e32, doi:10.1002/cp21.32 (2021). |
| 728 | 33 | in Mass Spectrometry Based Secretomics Mol Coll Proteomics 22, 100636 |
| 729 | | doi:10.1016/i menro 2023.100636 (2023) |
| 730 | 34 | Blume I. E. et al. Ranid deep and precise profiling of the plasma proteome with multi- |
| 732 | 54 | nanonarticle protein corona. Nat Commun 11, 3662, doi:10.1038/s41467-020-17033-7 |
| 732 | | (2020) |
| 734 | 35 | Eerdosi S <i>et al</i> Engineered nanoparticles enable deep proteomics studies at scale by |
| 735 | 00 | leveraging tunable nano-bio interactions. Proc Natl Acad Sci U.S.A. 119 , e2106053119 |
| 736 | | doi:10.1073/pnas.2106053119 (2022) |
| 737 | 36 | Donovan, M. K. R. <i>et al.</i> Functionally distinct BMP1 isoforms show an opposite pattern of |
| 738 | | abundance in plasma from non-small cell lung cancer subjects and controls. <i>PLoS One</i> |
| 739 | | 18 . e0282821. doi:10.1371/journal.pone.0282821 (2023). |
| 740 | 37 | Candia, J., Dava, G. N., Tanaka, T., Ferrucci, L. & Walker, K. A. Assessment of |
| 741 | | variability in the plasma 7k SomaScan proteomics assay. Sci Rep 12, 17147. |
| 742 | | doi:10.1038/s41598-022-22116-0 (2022). |
| 743 | 38 | Cordon, J. et al. Identification of Clinically Relevant Brain Endothelial Cell Biomarkers in |
| 744 | | Plasma. Stroke 54, 2853-2863, doi:10.1161/STROKEAHA.123.043908 (2023). |

| | ~ ~ | |
|-----|-----|---|
| 745 | 39 | Evans, D. S. et al. Proteomic Analysis of the Senescence-Associated Secretory |
| 746 | | Phenotype: GDF-15, IGFBP-2, and Cystatin-C Are Associated With Multiple Aging |
| 747 | | Traits. J Gerontol A Biol Sci Med Sci 79, doi:10.1093/gerona/glad265 (2024). |
| 748 | 40 | Tanaka, T. et al. Plasma proteomic biomarker signature of age predicts health and life |
| 749 | | span. <i>Elife</i> 9 , doi:10.7554/eLife.61073 (2020). |
| 750 | 41 | Stastna, M. & Van Eyk, J. E. Investigating the secretome: lessons about the cells that |
| 751 | | comprise the heart. Circ Cardiovasc Genet 5, 08-018, |
| 752 | | doi:10.1161/CIRCGENETICS.111.960187 (2012). |
| 753 | 42 | Samsonraj, R. M., Law, S. F., Chandra, A. & Pignolo, R. J. An unbiased proteomics |
| 754 | | approach to identify the senescence-associated secretory phenotype of human bone |
| 755 | | marrow-derived mesenchymal stem cells. Bone Rep 18, 101674. |
| 756 | | doi:10.1016/i.bonr.2023.101674 (2023). |
| 757 | 43 | Ozcan, S. et al. Unbiased analysis of senescence associated secretory phenotype |
| 758 | .0 | (SASP) to identify common components following different genotoxic stresses <i>Aging</i> |
| 759 | | (Albany NY) 8 1316-1329 doi:10.18632/aging 100971 (2016) |
| 760 | 44 | Wiley C. D. et al. SII AC Analysis Reveals Increased Secretion of Hemostasis-Related |
| 761 | | Factors by Sanascent Cells, Cell Ren 28, 3320-3337 e3325 |
| 762 | | doi:10.1016/i.celrep.2019.08.0/9 (2019) |
| 762 | 15 | Meilvang L et al. Starvation induces ranid degradation of selective autonbagy recentors |
| 703 | 40 | by ondesomal microautonbagy lournal of Coll Biology 217 , 3640-3655 (2010) |
| 704 | 16 | Herronz, N. et al. mTOP regulates MAPKAPK2 translation to control the sonescence |
| 705 | 40 | nerraliz, N. et al. InfOR regulates WAFRAFRZ translation to control the senescence- |
| 700 | | |
| 707 | 47 | (2013). |
| 768 | 47 | Laberge, R. M. et al. MITOR regulates the pro-tumongenic senescence-associated |
| 769 | | devide 4020/mehologic (2015) |
| 770 | 40 | 001.10.1030/1003195 (2015). |
| 771 | 40 | Sunre, K. et al. Nanoparticle enforment mass-spectrometry proteomics identifies |
| 772 | | protein-altering variants for precise point mapping. Nat Commun 15, 989, |
| //3 | 40 | dol:10.1038/s41467-024-45233-y (2024). |
| //4 | 49 | Ferdosi, S. et al. Engineered nanoparticles enable deep proteomics studies at scale by |
| //5 | | leveraging tunable nano-bio interactions. Proceedings of the National Academy of |
| //6 | | Sciences 119, e2106053119, doi:doi:10.10/3/pnas.2106053119 (2022). |
| 777 | 50 | Huang, I. et al. Protein Coronas on Functionalized Nanoparticles Enable Quantitative |
| 778 | | and Precise Large-Scale Deep Plasma Proteomics. <i>bioRxiv</i> , |
| 779 | | doi:10.1101/2023.08.28.555225 (2023). |
| 780 | 51 | Ishaq, A., Tchkonia, T., Kirkland, J. L., Siervo, M. & Saretzki, G. Palmitate induces DNA |
| 781 | | damage and senescence in human adipocytes in vitro that can be alleviated by oleic |
| 782 | | acid but not inorganic nitrate. Exp Gerontol 163 , 111798, |
| 783 | | doi:10.1016/j.exger.2022.111798 (2022). |
| 784 | 52 | Xue, W. J. et al. High glucose and palmitic acid induces neuronal senescence by |
| 785 | | NRSF/REST elevation and the subsequent mTOR-related autophagy suppression. <i>Mol</i> |
| 786 | | <i>Brain</i> 15 , 61, doi:10.1186/s13041-022-00947-2 (2022). |
| 787 | 53 | Maeda, M., Hayashi, T., Mizuno, N., Hattori, Y. & Kuzuya, M. Intermittent high glucose |
| 788 | | implements stress-induced senescence in human vascular endothelial cells: role of |
| 789 | | superoxide production by NADPH oxidase. <i>PLoS One</i> 10 , e0123169, |
| 790 | | doi:10.1371/journal.pone.0123169 (2015). |
| 791 | 54 | Minamino, T. et al. A crucial role for adipose tissue p53 in the regulation of insulin |
| 792 | | resistance. Nature Medicine 15, 1082-1087, doi:10.1038/nm.2014 (2009). |
| 793 | 55 | Schafer, M. J. et al. Exercise Prevents Diet-Induced Cellular Senescence in Adipose |
| 794 | | Tissue. <i>Diabetes</i> 65 , 1606-1615, doi:10.2337/db15-0291 (2016). |

| 705 | 50 | Yes Marcial Operative income sharing the start and income a life second in state of the second |
|------------|----|--|
| 795 | 56 | Xu, M. et al. Senolytics improve physical function and increase lifespan in old age. Nat |
| 796 | | Med 24, 1246-1256, doi:10.1038/s41591-018-0092-9 (2018). |
| 797 | 57 | Ogrodnik, M. et al. Obesity-Induced Cellular Senescence Drives Anxiety and Impairs |
| 798 | | Neurogenesis. <i>Cell Metabolism</i> 29 , 1061-1077 (2019). |
| 799 | 58 | Aversa, Z. et al. Calorie restriction reduces biomarkers of cellular senescence in |
| 800 | | humans. <i>Aging Cell</i> 23, e14038, doi:10.1111/acel.14038 (2024). |
| 801 | 59 | St Sauver, J. L. et al. Biomarkers of cellular senescence and risk of death in humans. |
| 802 | | Aging Cell 22, e14006, doi:10.1111/acel.14006 (2023). |
| 803 | 60 | Korbecki, J., Olbromski, M. & Dziegiel, P. CCL18 in the Progression of Cancer. Int J Mol |
| 804 | | Sci 21 . doi:10.3390/iims21217955 (2020). |
| 805 | 61 | Singh, A. et al. CCI 18 aggravates atherosclerosis by inducing CCR6-dependent T-cell |
| 806 | • | influx and polarization. Front Immunol 15 , 1327051, doi:10.3389/fimmu.2024.1327051 |
| 807 | | (2024) |
| 808 | 62 | Sin D D et al Serum PARC/CCL-18 concentrations and health outcomes in chronic |
| 808 800 | 02 | obstructive pulmonary disease. Am I Pospir Crit Care Mod 183 , 1187-1102 |
| 009 | | doi:10.1164/room 201008.1220 OC (2011) |
| 810 | 60 | UUI. 10. 1104/10011.201000-122000 (2011). |
| 811 | 63 | Suda, M. <i>et al.</i> Senolytic vaccination improves normal and pathological age-related |
| 812 | | phenotypes and increases lifespan in progeroid mice. Nat Aging 1, 1117-1126, |
| 813 | | doi:10.1038/s43587-021-00151-2 (2021). |
| 814 | 64 | Capone, E., Iacobelli, S. & Sala, G. Role of galectin 3 binding protein in cancer |
| 815 | | progression: a potential novel therapeutic target. J Transl Med 19 , 405, |
| 816 | | doi:10.1186/s12967-021-03085-w (2021). |
| 817 | 65 | Luo, M. et al. LGALS3BP: A Potential Plasma Biomarker Associated with Diagnosis and |
| 818 | | Prognosis in Patients with Sepsis. Infect Drug Resist 14, 2863-2871, |
| 819 | | doi:10.2147/IDR.S316402 (2021). |
| 820 | 66 | Pham, T. V., Henneman, A. A. & Jimenez, C. R. iq: an R package to estimate relative |
| 821 | | protein abundances from ion quantification in DIA-MS-based proteomics. Bioinformatics |
| 822 | | 36, 2611-2613, doi:10.1093/bioinformatics/btz961 (2020). |
| 823 | 67 | Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing |
| 824 | | and microarrav studies. Nucleic Acids Res 43, e47, doi:10.1093/nar/gkv007 (2015). |
| 825 | 68 | Yu, G., Wang, LG., Han, Y. & He, QY. clusterProfiler: an R Package for Comparing |
| 826 | | Biological Themes Among Gene Clusters, OMICS: A Journal of Integrative Biology 16. |
| 827 | | 284-287 doi:10.1089/omi.2011.0118 (2012) |
| 828 | 69 | Wu T et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data |
| 829 | 00 | The Innovation 2 100141 doi: https://doi.org/10.1016/j.yinp.2021.100141 (2021) |
| 830 | 70 | Shock N. W. Normal human aging : the Baltimore longitudinal study of aging (U.S. |
| 021 | 10 | Dopt of Hoalth and Human Services, Public Health Service, National Institutes of |
| 021 | | Health National Institute on Aging, Gerentelegy Research Center (1984) |
| 032 | 71 | Earrupei L. The Poltimere Longitudinal Study of Aging (PLSA): a 50 year long journey. |
| 033 | 11 | and plane for the future . (Corentel A Diel Sei Med Sei C2, 1440, 1440 |
| 834 | | and plans for the future. J Gerontol A Biol Sci Med Sci 63 , 1416-1419, |
| 835 | 70 | doi:10.1093/gerona/63.12.1416 (2008). |
| 836 | 72 | Schrack, J. A. et al. Assessing the "physical cliff": detailed quantification of age-related |
| 837 | | differences in daily patterns of physical activity. J Gerontol A Biol Sci Med Sci 69, 973- |
| 838 | | 979, doi:10.1093/gerona/glt199 (2014). |
| 839 | 73 | Ferrucci, L. et al. Subsystems contributing to the decline in ability to walk: bridging the |
| 840 | | gap between epidemiology and geriatric practice in the InCHIANTI study. J Am Geriatr |
| 841 | | Soc 48, 1618-1625, doi:10.1111/j.1532-5415.2000.tb03873.x (2000). |
| 842 | 74 | Candia, J. AO. et al. Assessment of Variability in the SOMAscan Assay. Scientific |
| 843 | | Reports 7 , 2045-2322 (2017). |

- 844 75 Duggan, M. R. et al. Proteome-wide analysis identifies plasma immune regulators of
- amyloid-beta progression. *Brain Behav Immun* **120**, 604-619,
- 846 doi:10.1016/j.bbi.2024.07.002 (2024).
- Friedman, J., Hastie, T. & Tibshirani, R. Regularization Paths for Generalized Linear
 Models via Coordinate Descent. *J Stat Softw* 33, 1-22 (2010).

849

850

851 **FIGURE LEGENDS**

852

853 Fig. 1 | Workflow for identification of SASP signatures from the aging plasma proteome. a, An in vitro model of senescent monocytes was developed by exposing THP-1 cells to IR and 854 measuring senescence markers. Further quantitative mass spectrometry proteomics was 855 performed on the secretome of these cells using the automated nanoparticle processing and 856 857 digestion platform, Proteograph. Age association of the differentially secreted proteins was evaluated using proteomic and phenotypic data from the BLSA and InCHIANTI aging cohorts. b, 858 859 The analysis pipeline used DIA-NN to identify monocyte secretome followed by filtering out the 860 bovine and shared peptides. Peptide quantities from each nanoparticle was rolled up to proteins to determine the differentially expressed proteins. 861

862

Fig. 2 | Establishing an IR-induced model of senescence in THP-1 monocytes. a, Representative fluorescence microscopy images from Edu incorporation assay and, b, corresponding quantification bar plots indicating reduced cellular incorporation of Edu by THP-1 cells 7 days after IR exposure. c, Bar plots showing increased expression of known senescence markers and, d, elevated SPiDER β-gal confirming induction of senescence in IR treated THP-1 cells. * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001.

869

Fig. 3 | Monocyte SASP is Associated with Age in the BLSA. a, Principal Component
Analysis (PCA) of Neat samples (protein level). b, PCA of 6 NP samples (protein level). c, PCA
of 14 NP samples (protein levels). For all PCA, only proteins present in all samples were used.
d, Monocyte SASP were identified using nanoparticle processing on the Proteograph. e, The
top 200 differentially expressed proteins were used for ontology analysis (p-value < 0.05, q-
value <0.1,Biological Process). f, Overlap between monocyte and fibroblast SASP. g, Ontology
analysis of overlapping SASP proteins between monocytes and fibroblasts.

Fig. 4 | Elastic Net Modeling Using SASP of Clinical Traits in the BLSA. a, 1550 Monocyte SASP are detected in the BLSA 7k SomaScan. b, Elastic Net models were trained on 80% of the BLSA cohort and used to predict clinical traits of the remaining 20%. Spearman correlations are shown between the predicted and observed values in the test set for each clinical trait. c, Elastic Net modeling was used for feature selection, and the number of Elastic Net Selected Proteins (ENSPs) implicated in each clinical trait are shown. c, ROC plot comparing the predictive potential (80% train, 20% test) of ENSPs positively associated with BMI to predict obesity with control-only

885 models, showing that ENSPs seem to provide additional predictive potential beyond age and 886 other controls alone.

887

Fig. 5 | Modeling of the fat content in BLSA using SASP candidates. a, Elastic Net models 888 were trained on 80% of the BLSA cohort and used to predict clinical traits of the remaining 20%. 889 890 Spearman correlations are shown between the predicted and observed values of the test set for 891 each clinical trait. b, Elastic Net modeling was used for feature selection, and the number of 892 Elastic Net Selected Proteins (ENSPs) implicated in each clinical trait are shown. c, ROC plot comparing the predictive potential (80% train, 20% test) of ENSPs positively associated with BMI 893 to predict obesity with control-only models, showing that ENSPs seem to provide additional 894 predictive potential beyond age and other controls alone. d, The correlation between observed 895 896 waist size and that predicted by Elastic Net Modeling (80% train, 20% test).

897

898 Fig. 6 | SASP-based associations show robust replication in the InCHIANTI aging study. a, 220 monocyte SASP were detected in both the BLSA (7k SomaScan) and InCHIANTI (1.3k 899 SomaScan). Elastic Net modeling was used for feature selection in both Inchianti and BLSA, and 900 901 linear models were constructed using only proteins selected in both studies for each trait. 902 Spearman's correlation of predicted values of linear models trained on the BLSA and observed 903 values in InCHIANTI are shown on the x-axis, and Spearman's correlation of predicted values of 904 linear models trained on InCHIANTI and observed values in the BLSA are shown on the y-axis b, 905 Binomial models were trained either using controls (age, sex) or controls + ENSPs in BLSA, then 906 used to predict obesity in Inchianti.

907

Fig. 7 | A high-impact SASP panel robustly predicts multiple clinical traits a, For a 14-trait 908 909 panel, proteins were ranked by the number of features for which they were selected via Elastic 910 Net in the BLSA, and the most frequently selected proteins are shown with their cross-trait 911 importance on the x-axis. Only proteins that were positively associated with negative traits such as BMI and CRP, and those that were inversely associated with positive traits such as mobility 912 were selected. Stars indicate those that were also detected in InCHIANTI. b, Linear models were 913 914 trained on 80% of the BLSA cohort and used to predict clinical traits in the remaining 20%. Spearman's correlation between the predicted and observed test values are shown. c, Linear 915 916 models were trained on 80% of the InCHIANTI cohort and used to predict clinical traits in the 917 remaining 20%. Spearman's correlation between the predicted and observed test values are 918 shown. d, Principal Component Analysis was used to condense the high-impact panel into a

- composite senescence burden score in the BLSA. Principal Component 1 was used to represent
- an eigengene for the high impact panel. With the BLSA cohort ranked from low to moderate to
- high senescence burden, linear trait trends reveal that positive traits HDL and Walking Pace show
- a negative trend, while negative traits BMI and CRP show a positive trend.
- 923
- 924
- 925

| | All | 20 to 40 | 40 to 60 | 60 to 70 | 80+ | Ν |
|----------------------|--------------------------|------------------------|-----------------------|---------------------|-----------------------|------|
| Count | 1330 | 70 | 256 | 736 | 268 | |
| age | 67.8 (14.1) | 33 (4.6) | 51.7 (6) | 70.8 (5.4) | 84 (3.2) | |
| Female Percent | 52.3 | 54.3 | 56.6 | 51.6 | 49.3 | |
| eGFR | 81.4 (17.7) | 106.2 (12.4) | 94.4 (13.2) | 77.1 (14.5) | 67.2 (12.8) | 1062 |
| BMI | 26.9 (4.6) | 25.1 (4.8) | 27.1 (4.8) | 27.5 (4.8) | 25.6 (3.3) | 1323 |
| Waist_Size | 88.5 (13.1) | 82.1 (12.1) | 86.2 (12.7) | 90.1 (13.5) | 88.1 (11.5) | 1283 |
| LDL | 106.4 (31.9) | 95.2 (28.1) | 111.3 (31.2) | 106.5 (33) | 103.3 (29) | 1054 |
| Triglycerides | 99.7 (50.5) | 88.6 (43.5) | 98.6 (52.6) | 102.5 (50.5) | 96.1 (49.4) | 1056 |
| CRP | 2.6 (4.4) | 1.5 (2.1) | 2 (3.1) | 2.8 (4.3) | 3.1 (6.2) | 998 |
| IL6 | 4.2 (3.5) | 3.7 (3.5) | 3.6 (2.5) | 4.3 (3.5) | 4.7 (4.6) | 996 |
| Fasting_Glucose | 96.6 (13.6) | 90.1 (6.9) | 95.1 (11.5) | 98.7 (15.4) | 95 (10.9) | 996 |
| De_Fat_Trunk | 13291.6 | 10026.7 | 13010.6 | 14333.8 | 11502.7 | 1022 |
| | (6209.7) | (5926.6) | (6411) | (6189.1) | (5143.4) | |
| De_Fat_Body | 26497.1 | 21591.9 | 26346.4 | 28237.5 | 22828.3 | 1022 |
| | (10343.6) | (10713.4) | (10389) | (10484.9) | (7788.7) | |
| De_Fat_Arms | 2589.9 | 2069.5 | 2582.5 | 2752.1 | 2264.5 | 1022 |
| De Fet Less | (1078.8) | (1025.4) | (1110.2) | (1097.8) | (826.3) | 4000 |
| De_Fat_Legs | 9724.2 | 8729.7 | 9880.8 (3818 4) | 10222.8 | 8217.9 | 1022 |
| CT Abd SubFat | 27620.3 | 25676.1 | 27001.3 | 29057 | 23814.1 | 711 |
| | (12738.4) | (18611.6) | (12284.8) | (13029.9) | (9508.3) | |
| CT Abd ViscFat | 9922.2 | 5408.9 | 7888.2 | 10761.3 | 10559.9 | 711 |
| | (5654.7) | (3678.7) | (4615.1) | (5847.2) | (5447.7) | |
| CT_Abd_ViscSubProp | 0.4 (0.2) | 0.2 (0.1) | 0.3 (0.2) | 0.4 (0.2) | 0.5 (0.3) | 653 |
| CT_Thigh_SubFat | 8389.1 | 8094.1 | 8510.6 | 8846.6 | 6832.2 | 900 |
| | (4539.1) | (5255.4) | (4324.1) | (4737.3) | (3458.5) | |
| CT_Thigh_IMFat | 1220.5 | 895.9 (489.6) | 1174.8 | 1256.4 | 1306.5 | 898 |
| Eat Dorcont | (509.8) 35.3 (9.4) | 29 5 (10 1) | (549.8) 34 3 (9 3) | (489.2) 37 (9.2) | (465.6) 33.6 (8.5) | 1022 |
| BD Svc | 122 0 (18 0) | 110 5 (12 6) | 118 1 (15 7) | 12/ 2 (18 7) | 130 4 (21 7) | 9022 |
| BP Dias | 122.9 (18.9) 66 (9.4) | 62 1 (7 1) | 68 1 (9 3) | 65 9 (9 6) | 64.8 (8.6) | 902 |
| ۵۱ _۵۱۵۵ ۸۱۲ | 5 8 (0 6) | 53(04) | 5.6 (0.6) | 5 9 (0 7) | 5 8 (0 3) | 965 |
| Chair Stands Pace 5 | 0.6 (0.2) | 0.7 (0.2) | 0.7 (0.2) | 0.5 (0.2) | 0.5 (0.2) | 975 |
| Chair Stands Pace 10 | 0.5 (0.2) | 0.7 (0.2) | 0.7 (0.2) | 0.5 (0.2) | 0.5 (0.2) | 975 |
| Lisual Gait Speed | 1.2(0.2) | 1 3 (0 2) | 1 3 (0 2) | 0.5 (0.2) | 11(02) | 972 |
| Banid Gait Speed | 1.2 (0.2) | 2.1 (0.2) | 2 (0.2) | 1.2 (0.2) | 1.1 (0.2) | 977 |
| Walk Pare AND Meter | 16(03) | 2.1 (0.3) 1 8 (0 2) | 2 (0.3) 1 7 (0 3) | 1 6 (0.4) | 1 3 (0.3) | 070 |
| | 1.0 (0.5) | 1.0 (0.2) | 1.7 (0.2) | 1.0 (0.2) | 1.3 (0.2) | 523 |
| HDL | 61.4 (17.3) | 60.1 (15.5) | 60.8 (18.1) | 61.3 (16.8) | 63.1 (18.5) | 1056 |

926

927 Table 1. Demographic and clinical traits in the Baltimore Longitudinal Study of Aging. Data

928 reported as mean (standard deviation).

929



Fig. 1 | **Workflow for identification of SASP signatures from the aging plasma proteome. a,** An in vitro model of senescent monocytes was developed by exposing THP-1 cells to IR and measuring senescence markers. Further quantitative mass spectrometry proteomics was performed on the secretome of these cells using the automated nanoparticle processing and digestion platform, Proteograph. Age association of the differentially secreted proteins was evaluated using proteomic and phenotypic data from the BLSA and InCHIANTI aging cohorts. **b**, The analysis pipeline used DIA-NN to identify monocyte secretome followed by filtering out the bovine and shared peptides. Peptide quantities from each nanoparticle was rolled up to proteins to determine the differentially expressed proteins.



Fig. 2 | Establishing an IR-induced model of senescence in THP-1 monocytes. a, Representative fluorescence microscopy images from Edu incorporation assay and, b, corresponding quantification bar plots indicating reduced cellular incorporation of Edu by THP-1 cells 7 days after IR exposure. c, Bar plots showing increased expression of known senescence markers and, d, elevated SPiDER β -gal confirming induction of senescence in IR treated THP-1 cells. * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001.



Fig. 3 | **Monocyte SASP is Associated with Age in the BLSA. a**, Principal Component Analysis (PCA) of Neat samples (protein level). **b**, PCA of 6 NP samples (protein level). **c**, PCA of 14 NP samples (protein levels). For all PCA, only proteins present in all samples were used. **d**, Monocyte SASP were identified using nanoparticle processing on the Proteograph. **e**, The top 200 differentially expressed proteins were used for ontology analysis (p-value < 0.05, q-value <0.1,Biological Process). **f**, Overlap between monocyte and fibroblast SASP. **g**, Ontology analysis of overlapping SASP proteins between monocytes and fibroblasts.



Fig. 4 | **Elastic Net Modeling Using SASP of Clinical Traits in the BLSA. a**, 1550 Monocyte SASP are detected in the BLSA 7k SomaScan. b, Elastic Net models were trained on 80% of the BLSA cohort and used to predict clinical traits of the remaining 20%. Spearman correlations are shown between the predicted and observed values in the test set for each clinical trait. c, Elastic Net modeling was used for feature selection, and the number of Elastic Net Selected Proteins (ENSPs) implicated in each clinical trait are shown. c, ROC plot comparing the predictive potential (80% train, 20% test) of ENSPs positively associated with BMI to predict obesity with control-only models, showing that ENSPs seem to provide additional predictive potential beyond age and other controls alone.



Fig. 5 | **Modeling of the fat content in BLSA using SASP candidates. a,** Elastic Net models were trained on 80% of the BLSA cohort and used to predict clinical traits of the remaining 20%. Spearman correlations are shown between the predicted and observed values of the test set for each clinical trait. b, Elastic Net modeling was used for feature selection, and the number of Elastic Net Selected Proteins (ENSPs) implicated in each clinical trait are shown. **c,** ROC plot comparing the predictive potential (80% train, 20% test) of ENSPs positively associated with BMI to predict obesity with control-only models, showing that ENSPs seem to provide additional predictive potential beyond age and other controls alone. d, The correlation between observed waist size and that predicted by Elastic Net Modeling (80% train, 20% test).



Fig. 6 | **SASP-based associations show robust replication in the InCHIANTI aging study. a,** 220 monocyte SASP were detected in both the BLSA (7k SomaScan) and InCHIANTI (1.3k SomaScan). Elastic Net modeling was used for feature selection in both Inchianti and BLSA, and linear models were constructed using only proteins selected in both studies for each trait. Spearman's correlation of predicted values of linear models trained on the BLSA and observed values in InCHIANTI are shown on the x-axis, and Spearman's correlation of predicted values of linear models trained on predicted values of linear models trained on the y-axis b, Binomial models were trained either using controls (age, sex) or controls + ENSPs in BLSA, then used to predict obesity in Inchianti.



